<DOC>
	<DOCNO>NCT01257074</DOCNO>
	<brief_summary>Herpes labialis common recurrent manifestation herpes simplex . The purpose study check non-inferiority efficacy safety penciclovir 10mg/g treatment Herpes Labialis comparison acyclovir 50mg/g .</brief_summary>
	<brief_title>Non-inferiority Comparison Efficacy Safety Penciclovir 10mg/g Acyclovir 50mg/g Treatment Recurrent Herpes Labialis</brief_title>
	<detailed_description>Study design : â€¢ Double blind non-inferiority prospective parallel-group , intend treat trial . Study design : - Experiment duration : 10 day - 3 visit ( day 1,5 10 ) - Erythema , papule , vesicle , ulcer , crust heal skin evaluation - Adverse event evaluation</detailed_description>
	<mesh_term>Herpes Labialis</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Penciclovir</mesh_term>
	<criteria>1 . Patients must able understand study procedure agree participate give write consent . 2 . Patients clinical diagnosis recurrent herpes labialis prodromal period ( stinging , itch , burn erythema ) onset sign / symptom last 1224 hour ; 3 . No history reaction topical product ; 1 . Pregnancy risk pregnancy . 2 . Lactation 3 . Use antiinflammatory immunosuppressive drug ( last 30 day prior study . ) 4 . Sunlight exposure last 15 day . 5 . Any pathology past medical condition interfere protocol . 6 . AINH use , hormonal antiinflammatory , analgesic immunosuppressive drug ( last 30 day study ) ; 7 . Patients immunodeficiency and/or immunosuppressive disease ; 8 . Sunlight exposure last 15 day ; 9 . Hypersensitivity component formula ; 10 . Other condition deem reasonable medical investigator disqualification individual study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Herpes Simplex</keyword>
</DOC>